Literature DB >> 30170070

Moracin derivatives from Morus Radix as dual BACE1 and cholinesterase inhibitors with antioxidant and anti-glycation capacities.

Su Hui Seong1, Manh Tuan Ha2, Byung Sun Min2, Hyun Ah Jung3, Jae Sue Choi4.   

Abstract

AIMS: Morus, a member of the family Moraceae and commonly known as the mulberry, comprises a pharmaceutically important plant group whose major constituents are the moracins. Moracin derivatives have received great attention because they exhibit a diverse range of biological functionalities. However, no studies have considered the anti-Alzheimer's disease (AD) and anti-glycation potential of moracin derivatives. MAIN
METHODS: We designed the current study to explore the anti-AD activity of moracin derivatives via in vitro inhibition of BACE1 and cholinesterase, their antioxidant activity via scavenging ONOO- and ABTS+ radicals, and their anti-diabetic activity through inhibition of advanced glycation end-products (AGEs) formation. Moreover, to define the mechanism of action of moracin derivatives in depth, we performed in silico molecular modeling using a computer-assisted drug design and modeling program. KEY
FINDINGS: Among the four Morus-derived moracins tested, moracin S, which has a prenyl moiety in the 2-aryl benzofuran scaffold, possessed the highest BACE1 inhibitory activity. It also, in a dose-dependent fashion, decreased ONOO--mediated bovine serum albumin (BSA) nitration and formation of AGEs and amyloid cross-β structures in the glycated BSA system, and it showed notable radical scavenging activity. In addition, enzyme kinetic and molecular docking studies demonstrated that moracin S is a potent, competitive BACE1 inhibitor that could interact with key catalytic aspartyl residues. SIGNIFICANCE: The prenyl moiety in the 2-aryl benzofuran structure plays a crucial role in inhibition of BACE1. These in vitro and in silico results provide valuable information for the design of anti-AD drugs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; BACE1; Drug design; Moracins; Morus alba

Mesh:

Substances:

Year:  2018        PMID: 30170070     DOI: 10.1016/j.lfs.2018.08.060

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Inhibition Mechanism of Components Isolated from Morus alba Branches on Diabetes and Diabetic Complications via Experimental and Molecular Docking Analyses.

Authors:  Ryeong-Ha Kwon; Niha Thaku; Binod Timalsina; Se-Eun Park; Jae-Sue Choi; Hyun-Ah Jung
Journal:  Antioxidants (Basel)       Date:  2022-02-14

2.  Comparison of Phytochemicals, Antioxidant, and In Vitro Anti-Alzheimer Properties of Twenty-Seven Morus spp. Cultivated in Thailand.

Authors:  Piya Temviriyanukul; Varittha Sritalahareuthai; Kriskamol Na Jom; Butsara Jongruaysup; Somying Tabtimsri; Kanchana Pruesapan; Sirinapa Thangsiri; Woorawee Inthachat; Dalad Siriwan; Somsri Charoenkiatkul; Uthaiwan Suttisansanee
Journal:  Molecules       Date:  2020-06-03       Impact factor: 4.411

3.  Insight into the PTP1B Inhibitory Activity of Arylbenzofurans: An In Vitro and In Silico Study.

Authors:  Srijan Shrestha; Su Hui Seong; Seul Gi Park; Byung Sun Min; Hyun Ah Jung; Jae Sue Choi
Journal:  Molecules       Date:  2019-08-09       Impact factor: 4.411

4.  Quantum Mechanical Predictions of the Antioxidant Capability of Moracin C Isomers.

Authors:  Angela Parise; Bruna Clara De Simone; Tiziana Marino; Marirosa Toscano; Nino Russo
Journal:  Front Chem       Date:  2021-04-21       Impact factor: 5.221

5.  De novo Transcriptome Analysis Revealed the Putative Pathway Genes Involved in Biosynthesis of Moracins in Morus alba L.

Authors:  Shengzhi Liu; Zhuoheng Zhong; Zijian Sun; Jingkui Tian; Kaisa Sulaiman; Eman Shawky; Hongwei Fu; Wei Zhu
Journal:  ACS Omega       Date:  2022-03-25

6.  The radical scavenging activity of moracins: theoretical insights.

Authors:  Quan V Vo; Nguyen Thi Hoa
Journal:  RSC Adv       Date:  2020-10-06       Impact factor: 4.036

7.  Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.

Authors:  Pradeep Paudel; Se Eun Park; Su Hui Seong; Hyun Ah Jung; Jae Sue Choi
Journal:  Int J Mol Sci       Date:  2019-12-10       Impact factor: 5.923

8.  Inhibition of PTP1B by farnesylated 2-arylbenzofurans isolated from Morus alba root bark: unraveling the mechanism of inhibition based on in vitro and in silico studies.

Authors:  Manh Tuan Ha; Srijan Shrestha; Thu Huong Tran; Jeong Ah Kim; Mi Hee Woo; Jae Sue Choi; Byung Sun Min
Journal:  Arch Pharm Res       Date:  2020-09-25       Impact factor: 4.946

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.